+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepatitis D - Pipeline Review, H2 2018

  • ID: 4658155
  • Drug Pipelines
  • 69 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • CN Bio Innovations Ltd
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • MORE
Hepatitis D - Pipeline Review, H2 2018

Summary

This disease pipeline guide, Hepatitis D - Pipeline Review, H2 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

This disease pipeline guide, Hepatitis D - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CN Bio Innovations Ltd
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • MORE
Introduction

Report Coverage

Hepatitis D - Overview

Hepatitis D - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis D - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis D - Companies Involved in Therapeutics Development

CN Bio Innovations Ltd

Eiger BioPharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Globeimmune Inc

Merck & Co Inc

Replicor Inc

Rodos BioTarget GmbH

SomaGenics Inc

Hepatitis D - Drug Profiles

Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-18000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myrcludex-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon lambda-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REP-2165 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Hepatitis D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Hepatitis B and Hepatitis D Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vanitaracin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis D - Dormant Projects

Hepatitis D - Product Development Milestones

Featured News & Press Releases

Sep 24, 2018: Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

Aug 06, 2018: Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

Jul 31, 2018: Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection

Jul 30, 2018: SomaGenics Awarded Multi-Year Funding for Hepatitis Delta Virus Therapeutic Program

Jun 11, 2018: Replicor Updates Mechanistic and Clinical Data Demonstrating High Rates of Functional Control of HBV and HDV Infection at the Science of HBV Cure 2018

Jun 04, 2018: Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018

Apr 17, 2018: Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018

Apr 13, 2018: Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

Apr 03, 2018: Replicor to Disclose Updated Data Demonstrating Functional Remission of HBV and HDV at the EASL International Liver Conference 2018

Apr 02, 2018: Eiger BioPharmaceuticals to Participate in Conferences in April

Mar 27, 2018: MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting

Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program

Mar 12, 2018: MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta

Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting

Feb 22, 2018: MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hepatitis D, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hepatitis D - Pipeline by CN Bio Innovations Ltd, H2 2018

Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H2 2018

Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Hepatitis D - Pipeline by Globeimmune Inc, H2 2018

Hepatitis D - Pipeline by Merck & Co Inc, H2 2018

Hepatitis D - Pipeline by Replicor Inc, H2 2018

Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2018

Hepatitis D - Pipeline by SomaGenics Inc, H2 2018

Hepatitis D - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Hepatitis D, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • CN Bio Innovations Ltd
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4658155
Adroll
adroll